MedTrace Logo

An Efficacy and Safety 6-months Study of SYNOLIS VA 80/160 and SYNOLIS VA 40/80 in the Treatment of Symptomatic Knee Osteoarthritis

NCT05829798 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2023-04-26

No results posted yet for this study

Summary

Multicentre, independent assessment study on SYNOLIS VA 80/160 and SYNOLIS VA 40/80 over a period of 24 weeks

Conditions

  • Osteoarthritis, Knee

Interventions

DEVICE

SYNOLIS VA 80/160

Single 4mL intra-articular injection of SYNOLIS VA 80/160

DEVICE

SYNOLIS VA 40/80

Single 2mL intra-articular injection of SYNOLIS VA 40/80

Sponsors & Collaborators

  • Noblewell

    collaborator INDUSTRY

  • Aptissen SA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2021-10-01
Completion
2021-10-01

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05829798 on ClinicalTrials.gov